Aitia is a company focused on the development and application of Causal AI and Digital Twins in the pharmaceutical industry. The company's main services include the discovery of drugs for neurodegenerative disorders, oncology, and immunology by revealing hidden biological mechanisms of diseases and creating Digital Twins. These Digital Twins are used to discover novel therapies and accelerate research and development in various diseases such as Alzheimer’s Disease, Parkinson’s Disease, Huntington’s Disease, multiple myeloma, prostate cancer, and pancreatic cancer. It was founded in 2000 and is based in Cambridge, Massachusetts.
Aitia's Product Videos
ESPs containing Aitia
The ESP matrix leverages data and analyst insight to identify and rank leading companies in a given technology landscape.
The digital twins & biosimulation market utilizes computer models to simulate biological processes and predict the behavior of drugs and devices. This market offers a range of solutions that enable the creation of "digital twins" — virtual replicas of biological systems that can be used to test the safety and efficacy of new therapies. Overall, the digital twins & biosimulation market aims to augm…
Aitia's Products & Differentiators
Gemini Digital Twin
Gemini Digital Twins enable the accurate simulation of gene and protein knockdowns at the individual patient level across “digital twins cohorts” to discover and validate novel drug targets. Gemini Digital Twins also enable the simulation of disease progression and drug response at the individual patient level across “digital twins cohorts” to simulate clinical trials to better select patients, and rapidly generate comparative effectiveness evidence.
Research containing Aitia
Get data-driven expert analysis from the CB Insights Intelligence Unit.
CB Insights Intelligence Analysts have mentioned Aitia in 1 CB Insights research brief, most recently on Dec 21, 2020.
Expert Collections containing Aitia
Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.
Aitia is included in 6 Expert Collections, including Artificial Intelligence.
Companies developing artificial intelligence solutions, including cross-industry applications, industry-specific products, and AI infrastructure solutions.
Digital Health 50
The most promising digital health startups transforming the healthcare industry
The digital health collection includes vendors developing software, platforms, sensor & robotic hardware, health data infrastructure, and tech-enabled services in healthcare. The list excludes pureplay pharma/biopharma, sequencing instruments, gene editing, and assistive tech.
Precision Medicine Tech Market Map
This CB Insights Tech Market Map highlights 160 precision medicine companies that are addressing 9 distinct technology priorities that pharmaceutical companies and healthcare providers face.
Drug Discovery Tech Market Map
This CB Insights Tech Market Map highlights 220 drug discovery companies that are addressing 12 distinct technology priorities that pharmaceutical companies face.
This collection includes companies applying technology to cancer care, diagnosis, and treatment. Examples include vendors offering cancer detection and diagnosis, oncology clinical decision support, real-world data, and AI oncology drug discovery.
Latest Aitia News
Nov 15, 2023
Charles River, Aitia form pact to tap AI for neurodegenerative and oncology research jkeenan Wed, 11/15/2023 - 13:47
Aitia Frequently Asked Questions (FAQ)
When was Aitia founded?
Aitia was founded in 2000.
Where is Aitia's headquarters?
Aitia's headquarters is located at 561 Windsor St., Cambridge.
What is Aitia's latest funding round?
Aitia's latest funding round is Corporate Minority.
How much did Aitia raise?
Aitia raised a total of $65.25M.
Who are the investors of Aitia?
Investors of Aitia include Charles River Laboratories, Paycheck Protection Program, Merck Global Health Innovation Fund, Celgene, Alexandria Venture Investments and 12 more.
Who are Aitia's competitors?
Competitors of Aitia include Cyclica, Unlearn, BERG, Insilico Medicine, InSilicoTrials and 7 more.
What products does Aitia offer?
Aitia's products include Gemini Digital Twin and 1 more.
Who are Aitia's customers?
Customers of Aitia include Pfizer, Mercks, AbbVie, Sanofi and Servier.
Compare Aitia to Competitors
Standigm is an AI-driven drug discovery company operating in the pharmaceutical industry. The company's main services include the use of proprietary AI platforms for novel target identification, lead generation, and the creation of commercially valuable drug pipelines. Standigm primarily sells to the pharmaceutical and healthcare industries. It was founded in 2015 and is based in Seoul, South Korea.
Atomwise develops machine learning-based discovery engines and uses deep learning and artificial intelligence (AI)-based neural networks to help discover new medicines. It predicts drug candidates for pharmaceutical companies, start-ups, and research institutions and designs drugs using computational drug design. The company was founded in 2012 and is based in San Francisco, California.
Healx provides drug discovery services. The company manufactures drugs using technology to bring treatments for rare diseases to patients. Its platform, Healnet, helps face challenges by analyzing drug and disease data points. The company was founded in 2014 and is based in Cambridge, U.K.
Aria Pharmaceuticals is a preclinical-stage pharmaceutical company that focuses on the discovery and development of novel, small molecule therapies in the pharmaceutical industry. The company's main service is the development of new treatments for complex and hard-to-treat diseases using their proprietary Symphony platform, which combines biomedical data and artificial intelligence to increase the success rates of drug discovery. Aria Pharmaceuticals primarily serves the healthcare sector, specifically targeting areas where new therapies are most needed. It was founded in 2014 and is based in Palo Alto, California.
Insitro provides data-driven drug discovery and development solutions. It combines machine learning and modern biological tools to enable predictive models. The company was founded in 2018 and is based in South San Francisco, California.
Gero develops data analysis methods to identify potential targets for therapeutic intervention against age-related diseases and aging. It uses a statistical physics model to analyze gene networks' stability and predict their dynamics over time. It allows for linking gene network stability with mortality. It was founded in 2015 and is based in Singapore.